Canada Markets closed

Eliem Therapeutics, Inc. (ELYM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.64-0.70 (-6.17%)
At close: 04:00PM EST
10.64 0.00 (0.00%)
After hours: 06:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close11.34
Open11.27
Bid10.00 x 1100
Ask13.00 x 1400
Day's Range10.52 - 12.12
52 Week Range10.52 - 29.69
Volume30,403
Avg. Volume104,338
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

    Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive disorder (MDD) and perimenopausal depression (PMD) clinical trials Continued to enroll ETX-810’s two Phase 2a chronic pain clinical trials, with topline data anticipated in the first half of 2022 On track to progress Kv7.2/3 channel opener program into Investigational New Drug (IND)-enabling studies

  • GlobeNewswire

    Eliem Therapeutics to Participate at Four Upcoming Investor Conferences

    SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences. Virtual Guggenheim 3rd Annual Neu

  • GlobeNewswire

    Eliem Therapeutics Reports Second Quarter Financial Results

    On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along with existing cash, provides cash runway through late 2023 SEATTLE and CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address u